This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or high-grade gliomas that have come back (recurred) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Condition: Solid Tumors Intervention: Drug: Selinexor
Principal Investigator:
Josephine HaDuong, MD
Research Coordinator:
Tina Templeman
(714) 509-8646
Visit clinicaltrials.gov for more information about this trial.
- IRB Number: 151076
- Sponsor: COG
- Protocol Number: ADVL1414
- NCT Number: NCT02323880
- Research Type: Brain Tumor/Central Nervous System/Neuro-Oncology, Recurrent/Refractory Cancer, Solid Tumors
- Phase: I
- Status: Active - Open to Enrollment
Key Inclusion Criteria:
- Age:12 Months to 21 Years
- Patients must have a body surface area (BSA) >= 0.84 m^2Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled
- Patients must be able to swallow tablets wholeStandard COG Phase 1 organ function requirements
Key Exclusion Criteria:
- Patients with body mass index (BMI) < 3rd percentile for age are not eligible.
- Patients with grade 3 ataxia or grade >1 extrapyramidal movement disorder are not eligible
- Patients with known macular degeneration, uncontrolled glaucoma, or cataracts are not eligible
